Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?

J Clin Oncol. 2017 Dec 20;35(36):3999-4002. doi: 10.1200/JCO.2017.74.5752. Epub 2017 Oct 26.

Authors

Andrew Berchuck¹, Angeles Alvarez Secord¹, Haley A Moss¹, Laura J Havrilesky¹

Affiliation

¹ Andrew Berchuck, Angeles Alvarez Secord, Haley A. Moss, and Laura J. Havrilesky, Duke University Medical Center, Durham, NC.

PMID: 29072978
DOI: 10.1200/JCO.2017.74.5752

No abstract available

MeSH terms

Biomarkers, Tumor / genetics*
Clinical Decision-Making
Cost-Benefit Analysis
Drug Costs
Female
Genetic Predisposition to Disease
Genetic Variation*
Humans
Maintenance Chemotherapy
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / economics
Ovarian Neoplasms / enzymology
Ovarian Neoplasms / genetics
Phenotype
Poly(ADP-ribose) Polymerase Inhibitors / adverse effects
Poly(ADP-ribose) Polymerase Inhibitors / economics
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
Precision Medicine* / economics

Substances

Biomarkers, Tumor
Poly(ADP-ribose) Polymerase Inhibitors